Interest in the abnormal metabolism exhibited by cancer cells has been reawakened by the discovery of oncogenic mutations in metabolic enzymes, and by tools that monitor metabolism in living cells. Existing and emerging therapies aim to target this abnormal metabolism in various ways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout


Author information
Authors and Affiliations
Ethics declarations
Competing interests
W.G.K. is a consultant to FibroGen Pharmaceuticals and to Agios Pharmaceuticals. C.B.T. is a founder and chair of the advisory board of Agios Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Kaelin, W., Thompson, C. Clues from cell metabolism. Nature 465, 562–564 (2010). https://doi.org/10.1038/465562a
Published:
Issue Date:
DOI: https://doi.org/10.1038/465562a
This article is cited by
-
PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells
Oncogene (2022)
-
AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
Cell Communication and Signaling (2020)
-
A multicentre clinical validation of AminoIndex Cancer Screening (AICS)
Scientific Reports (2019)
-
FELLA: an R package to enrich metabolomics data
BMC Bioinformatics (2018)
-
Novel non-invasive early detection of lung cancer using liquid immunobiopsy metabolic activity profiles
Cancer Immunology, Immunotherapy (2018)